BioStock Analytics - Biostock

WEEKLY: The Nordic Pulse

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Egetis wins FDA approval, Indices retreat across the board – the Nordic Pulse | 2026:40

Nanexa lands billion-euro Novo deal, Nordic index slides nearly three per cent – the Nordic Pulse | 2026:39

QUARTERLY: The State of Nordic Biopharma

A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3

State of Nordic Biopharma | Q2 2026

State of Nordic Biopharma | Q1 2026

BioStock Analytics

We deliver accessible sector news, in-depth company insights alongside trusted data and industry-wide market intelligence.

Consensus Analysis

Consensus Analysis | Ascendis Pharma | 2026-09-14

Consensus Analysis | Novonesis | 2026-09-08

Consensus Analysis | Coloplast | 2026-09-01

BioVal – rNPV analyses

BioVal™ analysis: Alzinova’ ALZ-101 valued at SEK 7.1B

BioVal™ analysis: Elicera Therapeutics’ ELC-301 valued at SEK 631M

Consensus Analysis (cont.)

Consensus Analysis | Zealand Pharma | 2026-08-25

Consensus Analysis | Genmab | 2026-08-21

Consensus Analysis | Novo Nordisk | 2026-08-18

Consensus Analysis | SOBI | 13 August 2026

Consensus Analysis | Getinge | 11 August 2026

Consensus Analysis | Astra Zeneca | 6 August 2026

Consensus Analysis | Novo Nordisk | 19 May 2026

WEEKLY: The Nordic Pulse (cont.)

Oncopeptides rides the CHMP wave, AstraZeneca adds eight more years – the Nordic Pulse | 2026:38

AstraZeneca’s hat-trick, a broad sell-off and Alzinova funds its Alzheimer’s push – the Nordic Pulse | 2026:37

AstraZeneca strikes again, BioArctic’s Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36

BioArctic’s home-run, a third win for Astra’s Tezspire and a path to phase III for Lytix – the Nordic Pulse | 2026:35

AstraZeneca fires three barrels, Implantica enters the US – the Nordic Pulse | 2026:34

Demant raises the bar, XVIVO clears hearts and Zealand cashes in – the Nordic Pulse | 2026:33

Novo raises outlook, BioInvent breaks through, Nordics tread water – the Nordic Pulse | 2026:32

Novo misses, AstraZeneca holds steady, Alvotech clears FDA – the Nordic Pulse | 2026:31

Novo sues Lilly, Alligator collapses, Lundbeck completes Phase III – the Nordic Pulse | 2026:30

Leqembi under the skin, Wegovy wins Europe, Sobi lifts guidance – the Nordic Pulse | 2026:29

AstraZeneca drags the index, Ascelia contests the FDA and board drama at BICO – the Nordic Pulse | 2026:28

Hansa closes, AlzeCure soars, Ascelia falters – the Nordic Pulse | 2026:27